QNCX Strangle Strategy

QNCX (Quince Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large molecules, directly to affected bone areas like fractures and disease sites. Leading their pipeline is NOV004, an anabolic peptide meticulously designed to pinpoint and accumulate its therapeutic action precisely at bone fracture locations. The company, previously known as Cortexyme, Inc., officially rebranded as Quince Therapeutics, Inc. in August 2022. Established in 2012, Quince Therapeutics is headquartered in South San Francisco, California.

QNCX (Quince Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $5.3M, a beta of 1.37 versus the broader market, a 52-week range of 0.79-45.5, average daily share volume of 4.9M, a public-listing history dating back to 2019, approximately 36 full-time employees. These structural characteristics shape how QNCX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.37 indicates QNCX has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.

What is a strangle on QNCX?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current QNCX snapshot

As of June 30, 2026, spot at $19.24, ATM IV 39.80%, IV rank 3.77%, expected move 11.41%. The strangle on QNCX below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.

Why this strangle structure on QNCX specifically: QNCX IV at 39.80% is on the cheap side of its 1-year range, which favors premium-buying structures like a QNCX strangle, with a market-implied 1-standard-deviation move of approximately 11.41% (roughly $2.20 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated QNCX expiries trade a higher absolute premium for lower per-day decay. Position sizing on QNCX should anchor to the underlying notional of $19.24 per share and to the trader's directional view on QNCX stock.

QNCX strangle setup

The QNCX strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With QNCX near $19.24, the first option leg uses a $20.20 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed QNCX chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 QNCX shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$20.20	N/A
Buy 1	Put	$18.28	N/A

QNCX strangle risk and reward

Net Premium / Debit: N/A
Max Profit (per contract): Unbounded
Max Loss (per contract): Unbounded
Breakeven(s): None on modeled curve
Risk / Reward Ratio: N/A

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

QNCX strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on QNCX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use strangle on QNCX

Strangles on QNCX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the QNCX chain.

QNCX thesis for this strangle

The market-implied 1-standard-deviation range for QNCX extends from approximately $17.04 on the downside to $21.44 on the upside. A QNCX long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current QNCX IV rank near 3.77% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on QNCX at 39.80%. As a Healthcare name, QNCX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to QNCX-specific events.

QNCX strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. QNCX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move QNCX alongside the broader basket even when QNCX-specific fundamentals are unchanged. Always rebuild the position from current QNCX chain quotes before placing a trade.

Frequently asked questions

What is a strangle on QNCX?: A strangle on QNCX is the strangle strategy applied to QNCX (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With QNCX stock trading near $19.24, the strikes shown on this page are snapped to the nearest listed QNCX chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are QNCX strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the QNCX strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 39.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a QNCX strangle?: The breakeven for the QNCX strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current QNCX market-implied 1-standard-deviation expected move is approximately 11.41%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on QNCX?: Strangles on QNCX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the QNCX chain.
How does current QNCX implied volatility affect this strangle?: QNCX ATM IV is at 39.80% with IV rank near 3.77%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.